Oct4 found to be a prognostic marker for digestive cancers

November 22, 2016

(HealthDay)—Octamer-binding transcription factor 4 (Oct4) is a predictive marker for patients with digestive system cancers, according to a review and meta-analysis published online Nov. 7 in the Journal of Gastroenterology and Hepatology.

Zhiqiang Chen, from the First Affiliated Hospital of Nanjing Medical University in China, and colleagues conducted a literature review to identify studies assessing the potential role of Oct4 as a in tumors.

The researchers identified 13 eligible studies that included 1,538 . Elevated Oct4 expression was significantly associated with poor overall survival (pooled hazard ratio [HR], 2.183), disease-free survival (pooled HR, 1.973), and recurrence-free survival (pooled HR, 2.209) in digestive system malignancies. Cancer type, sample size, study quality, and laboratory detection method did not affect the significant prognostic value of Oct4. In addition, Oct4 expression was found to be an independent predictive factor for overall survival (HR, 2.068). There was no significant association between Oct4 and clinicopathological features of digestive system malignancies.

"This study provided evidence of Oct4 and/or its closely-related homolog protein as a factor for patients with digestive system cancers," the authors write. "More large-scale clinical studies on the prognostic value of Oct4 are warranted."

Explore further: Protein kinase Akt identified as arbiter of cancer stem cell fate, paper reports

More information: Full Text (subscription or payment may be required)

Related Stories

Protein kinase Akt identified as arbiter of cancer stem cell fate, paper reports

December 20, 2012
(Medical Xpress)—The protein kinase Akt is a key regulator of cell growth, proliferation, metabolism, survival, and death. New work on Akt's role in cancer stem cell biology from the lab of senior author Honglin Zhou, MD, ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.